Business · 26/02/2018Updated: 10/17/2026 · 1 min read
FDA Announces Public Meeting of Psychopharmacologic Drugs Advisory Committee for Regulatory Advice
Summary
The FDA is hosting a public advisory committee meeting to gather input on regulatory issues related to psychopharmacologic drugs, with a public docket open for comments on the proposed meeting and its agenda.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →